Amicogen, Inc. Logo

Amicogen, Inc.

092040.KQ

(0.0)
Stock Price

4.540,00 KRW

-6.37% ROA

-16.21% ROE

-4.45x PER

Market Cap.

350.254.620.900,00 KRW

45.34% DER

0% Yield

-14.51% NPM

Amicogen, Inc. Stock Analysis

Amicogen, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Amicogen, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Amicogen, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Amicogen, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Amicogen, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Amicogen, Inc. Revenue
Year Revenue Growth
2013 23.180.942.200
2014 27.331.643.810 15.19%
2015 32.457.291.970 15.79%
2016 68.968.044.740 52.94%
2017 73.665.135.170 6.38%
2018 94.521.965.170 22.07%
2019 115.180.889.370 17.94%
2020 115.856.068.710 0.58%
2021 124.880.967.140 7.23%
2022 144.295.727.340 13.45%
2023 158.283.264.160 8.84%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Amicogen, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 821.511.270
2014 1.045.077.669 21.39%
2015 2.288.380.710 54.33%
2016 2.810.911.640 18.59%
2017 4.770.211.480 41.07%
2018 5.182.706.800 7.96%
2019 5.376.120.360 3.6%
2020 6.281.966.070 14.42%
2021 10.842.949.620 42.06%
2022 12.435.973.150 12.81%
2023 12.604.997.680 1.34%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Amicogen, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 39.773.630
2014 30.781.260 -29.21%
2015 96.399.690 68.07%
2016 225.923.720 57.33%
2017 258.882.310 12.73%
2018 497.219.810 47.93%
2019 327.001.780 -52.05%
2020 129.335.190 -152.83%
2021 180.541.800 28.36%
2022 160.691.170 -12.35%
2023 202.357.440 20.59%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Amicogen, Inc. EBITDA
Year EBITDA Growth
2013 9.774.925.300
2014 10.716.140.880 8.78%
2015 4.754.143.680 -125.41%
2016 9.452.525.700 49.71%
2017 10.006.417.930 5.54%
2018 10.218.797.420 2.08%
2019 7.462.618.740 -36.93%
2020 12.644.433.970 40.98%
2021 6.143.290.210 -105.83%
2022 7.738.934.890 20.62%
2023 19.331.879.720 59.97%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Amicogen, Inc. Gross Profit
Year Gross Profit Growth
2013 11.893.314.400
2014 13.697.613.130 13.17%
2015 11.581.387.460 -18.27%
2016 23.541.187.870 50.8%
2017 24.530.100.100 4.03%
2018 30.205.163.570 18.79%
2019 48.231.958.110 37.38%
2020 44.548.418.590 -8.27%
2021 44.641.034.190 0.21%
2022 45.762.147.180 2.45%
2023 58.035.479.520 21.15%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Amicogen, Inc. Net Profit
Year Net Profit Growth
2013 7.574.696.320
2014 7.563.006.730 -0.15%
2015 2.065.660.870 -266.13%
2016 1.588.678.630 -30.02%
2017 -4.605.846.380 134.49%
2018 40.168.083.220 111.47%
2019 86.718.370 -46220.15%
2020 31.604.368.950 99.73%
2021 3.732.651.490 -746.7%
2022 -47.219.840.560 107.9%
2023 -12.500.794.280 -277.73%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Amicogen, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 499
2014 442 -12.93%
2015 118 -273.73%
2016 87 -35.63%
2017 -494 117.61%
2018 2.091 123.63%
2019 5 -52175%
2020 1.644 99.76%
2021 192 -756.25%
2022 -2.390 108.03%
2023 -633 -278.16%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Amicogen, Inc. Free Cashflow
Year Free Cashflow Growth
2013 3.832.242.180
2014 -176.759.010 2268.06%
2015 6.536.434.560 102.7%
2016 -2.549.425.790 356.39%
2017 432.504.090 689.46%
2018 -8.042.495.790 105.38%
2019 -10.499.975.760 23.4%
2020 -4.987.034.510 -110.55%
2021 -39.235.415.380 87.29%
2022 -68.321.232.550 42.57%
2023 -13.043.640.060 -423.79%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Amicogen, Inc. Operating Cashflow
Year Operating Cashflow Growth
2013 6.623.420.980
2014 4.425.691.460 -49.66%
2015 12.342.714.190 64.14%
2016 11.276.966.410 -9.45%
2017 11.882.053.270 5.09%
2018 2.840.022.740 -318.38%
2019 8.760.340.930 67.58%
2020 8.865.817.780 1.19%
2021 8.073.460.490 -9.81%
2022 -22.413.068.120 136.02%
2023 1.246.234.090 1898.46%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Amicogen, Inc. Capital Expenditure
Year Capital Expenditure Growth
2013 2.791.178.800
2014 4.602.450.470 39.35%
2015 5.806.279.630 20.73%
2016 13.826.392.200 58.01%
2017 11.449.549.180 -20.76%
2018 10.882.518.530 -5.21%
2019 19.260.316.690 43.5%
2020 13.852.852.290 -39.04%
2021 47.308.875.870 70.72%
2022 45.908.164.430 -3.05%
2023 14.289.874.150 -221.26%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Amicogen, Inc. Equity
Year Equity Growth
2013 41.390.545.390
2014 50.019.561.680 17.25%
2015 110.245.736.260 54.63%
2016 107.158.433.560 -2.88%
2017 115.922.238.650 7.56%
2018 160.289.377.100 27.68%
2019 158.407.861.070 -1.19%
2020 192.733.917.760 17.81%
2021 232.873.521.340 17.24%
2022 169.777.938.029 -37.16%
2023 171.368.305.390 0.93%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Amicogen, Inc. Assets
Year Assets Growth
2013 44.361.034.580
2014 54.367.133.230 18.4%
2015 159.843.638.430 65.99%
2016 146.330.483.990 -9.23%
2017 163.514.711.990 10.51%
2018 231.214.349.740 29.28%
2019 241.401.291.320 4.22%
2020 283.367.945.100 14.81%
2021 411.224.497.260 31.09%
2022 429.651.956.810 4.29%
2023 452.021.904.360 4.95%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Amicogen, Inc. Liabilities
Year Liabilities Growth
2013 2.970.489.190
2014 4.347.571.550 31.67%
2015 49.597.902.170 91.23%
2016 39.172.050.430 -26.62%
2017 47.592.473.340 17.69%
2018 70.924.972.650 32.9%
2019 82.993.430.250 14.54%
2020 90.634.027.340 8.43%
2021 178.350.975.920 49.18%
2022 259.874.018.770 31.37%
2023 280.653.598.960 7.4%

Amicogen, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8099.96
Net Income per Share
-1450.09
Price to Earning Ratio
-4.45x
Price To Sales Ratio
2.19x
POCF Ratio
-194.48
PFCF Ratio
-8.04
Price to Book Ratio
0.98
EV to Sales
2.05
EV Over EBITDA
24.77
EV to Operating CashFlow
-501.32
EV to FreeCashFlow
-7.54
Earnings Yield
-0.22
FreeCashFlow Yield
-0.12
Market Cap
350,25 Bil.
Enterprise Value
328,46 Bil.
Graham Number
14673.63
Graham NetNet
-8932.66

Income Statement Metrics

Net Income per Share
-1450.09
Income Quality
0.02
ROE
-0.2
Return On Assets
-0.05
Return On Capital Employed
0.01
Net Income per EBT
5.81
EBT Per Ebit
-1.94
Ebit per Revenue
0.01
Effective Tax Rate
0.66

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.32
Operating Profit Margin
0.01
Pretax Profit Margin
-0.02
Net Profit Margin
-0.15

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-33.17
Free CashFlow per Share
-2206.13
Capex to Operating CashFlow
65.52
Capex to Revenue
-0.27
Capex to Depreciation
-3.21
Return on Invested Capital
-0
Return on Tangible Assets
-0.06
Days Sales Outstanding
123.23
Days Payables Outstanding
152.86
Days of Inventory on Hand
169.4
Receivables Turnover
2.96
Payables Turnover
2.39
Inventory Turnover
2.15
Capex per Share
-2172.96

Balance Sheet

Cash per Share
1.972,24
Book Value per Share
6.599,29
Tangible Book Value per Share
8549.99
Shareholders Equity per Share
6599.29
Interest Debt per Share
2992.05
Debt to Equity
0.45
Debt to Assets
0.13
Net Debt to EBITDA
-1.64
Current Ratio
0.71
Tangible Asset Value
168,90 Bil.
Net Current Asset Value
-124,74 Bil.
Invested Capital
0.45
Working Capital
-63,11 Bil.
Intangibles to Total Assets
0.01
Average Receivables
56,53 Bil.
Average Payables
48,16 Bil.
Average Inventory
47757526935
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Amicogen, Inc. Dividends
Year Dividends Growth
2014 120
2015 100 -20%

Amicogen, Inc. Profile

About Amicogen, Inc.

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company offers specialty enzymes, including CX, SP, etc. for pharmaceutical, food, chemical, and energy industries. It also provides new bio-ingredients, such as N-acetylglucosamine for skin moisturizing and joint health; pinitol/D-chiro-inositol; collagen peptide and collagen tripeptide for skin and health; chitoslim and chitosan oligosaccharides; and lactic acid bacteria, as well as fucoxanthin, curezyme, food enzyme, and bamboo salt. In addition, the company offers K-nutra, a healthcare brand; and KeyClean, a disinfectant brand. Further, it provides protein purification resins. The company was founded in 2000 and is headquartered in Jinju-si, South Korea.

CEO
Mr. Yong Chul Shin
Employee
216
Address
64, Dongbu-ro
Jinju-Si, 52621

Amicogen, Inc. Executives & BODs

Amicogen, Inc. Executives & BODs
# Name Age
1 Mr. Yong Chul Shin
Chief Executive Officer and President
70

Amicogen, Inc. Competitors

ALTEOGEN Inc. Logo
ALTEOGEN Inc.

196170.KQ

(0.0)
Hanatour Service Inc. Logo
Hanatour Service Inc.

039130.KS

(1.5)
Com2uS Corporation Logo
Com2uS Corporation

078340.KQ

(0.0)
Osstem Implant Co., Ltd. Logo
Osstem Implant Co., Ltd.

048260.KQ

(0.0)
Paradise Co., Ltd. Logo
Paradise Co., Ltd.

034230.KQ

(0.0)